This trial studies how well [18F]PARPi positron emission tomography (PET)/magnetic resonance imaging (MRI) works in imaging patients with brain tumors that are new or suspected to have come back (recurrent). [18F]PARPi is a radiotracer used with PET/MRI scans to take pictures of brain tumors. This study may help researchers understand how [18F]PARPi works.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04173104.
PRIMARY OBJECTIVE:
I. To obtain data on uptake of fluorine F 18 PARP inhibitor ([18F]-PARPi) and its kinetics in brain tumors and/or treatment related changes.
EXPLORATORY OBJECTIVES:
I. To obtain data on tumor uptake of [18F]-PARPi PET/MR with PARP1/2 expression in resected tumor tissue.
II. To obtain data on systemic tumor uptake of [18F]-PARPi in patients with metastases to the brain and known systemic tumors.
III. To obtain data on potential toxicity of [18F]-PARPi administration.
OUTLINE:
Patients receive fluorine F 18 PARP inhibitor intravenously (IV) and undergo PET/MRI over 60 minutes. Patients then undergo 2 additional PET/MRI scans at 60 and 120 minutes post-injection at the discretion of the principal investigator.
After completion of study, patients are followed up at 1-3 and 30 days (and also at 60 days for patients who undergo surgery).
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationMemorial Sloan Kettering Cancer Center
Principal InvestigatorRobert J. Young
